Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh good I am not the only one lol. My Avg is 26 cents. Tried to Avg down put Fidelity will not allowing buying because they are not pink sheet current. Isn't that nice of them to look after me like that? Not!
According to the company, initial indications for NR2F6 activators include rheumatoid arthritis, inflammatory bowel disease and psoriasis, while indications for blockers include bladder cancer, myelodysplastic syndrome (a group of disorders caused by blood cells not formed or not working properly), and lung cancer.
Additional potential indications are solid tumors, acute leukemia and chronic graft-versus-host disease, which consists in the attack of the host’s cells by transplanted stem cells.
https://lupusnewstoday.com/2018/08/31/molecules-targeting-immune-protein-nr2f6-eyed-as-therapy-lupus/
Can someone dig up anything on this guy?
"We have identified a handful of compounds representing three different structural classes that inhibit NR2F6 in our primary screening assay," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-reports-success-of-its-nr2f6-small-molecule-screening-program-for-treating-autoimmune-diseases-868309898.html
What this means to our small molecule drug development programs is CBD appears when used with other compounds to amplify the desired outcome. Our current pipeline of NR2F6 small molecules both augment and inhibit interleukin-17 production, we see potential synergy between today's disclosed data and our ongoing small molecule programs."
https://www.gurufocus.com/news/956445/regen-biopharma-successfully-treats-rheumatoid-arthritis-using-cannabidiol-cbd-based-immune-modulatory-treatments
8k on perfered shares. 2014.
https://www.sec.gov/Archives/edgar/data/1589150/000160706214000097/regen20140918form8k.htm
That deal is probably coming next week?
ILNS had a lincence deal with PFE and GSK. AZ drug in Phase three. It failed ph 3. ILNS just went to nothing.
Reminded me of spng and ILNS. I struck out on both those. Hopefully this is not strike three!
Kinda messed up that I have been holding ten years or do at 26 cents and all you newbies jumping on the band wagon are making the money. I tried to buy but Fidelity won't let buying because they are not pink sheet current. I even called Fidelity they would not budge. Oh well.
What brokerage are you guys using? Fidelity and Webull won't let you buy.
shall become nonexclusive.
KCL Therapeutics, Inc. is a wholly owned subsidiary of Regen Biopharma, Inc.
Anyone know about kcl?
I hope at least 26 cents so I can break even!
https://www.oedigital.com/news/483271-opt-powerbuoy-tested-at-deepstar-s-zero-carbon-power-for-electric-subsea-operations-project
members of the Texas-based consortium include Chevron, CNOOC, Equinor, ExxonMobil, JX Nippon, Occidental, Petrobras, Shell, and Woodside.
The project is expected to complete in March 2021
What the heck is going on? Been noticing my account going up that I hardly ever look at. Been holding this since May 2010! If this goes to a dollar I will retire! Very strange that this has not traded hardly at all for ten years?
This is a little concerning. I just got a text alert on my phone. I thought it was an amber alert. It was an alert that covid19 is spiking in San Antonio Texas and to stay home. Also on KSAT dot com, local news talks about possible delays in testing. I posted screen shots on stock twits Aytu board if you want to see them. I don't know how to do that here?
What ever happened to ash111?
This will probably drop under 10 cents.
1 to 35 RS Aug 10th
No trades AH?
CRMD. Watch unusual volume. Supposedly data coming?
Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress
Globe Newswire FOLLOW
May 03, 2018 11:00am Comments
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), today reported that preliminary results from a study of Quell® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12, 2018.
The study was conducted by Dr. Robert Jamison and his colleagues at the Brigham and Women's Hospital Pain Management Center in Boston, MA. The poster presentation is titled "Efficacy of high-frequency transcutaneous electrical nerve stimulation for chronic low back pain: does hypersensitivity matter?" and includes the following key findings:
Subjects in the experimental (Quell) group demonstrated reduced pain intensity compared to control subjects.
Subjects in the experimental group exhibited reduced pain interference with function and pain catastrophizing compared to the control group.
Subjects in the experimental group with greater sensitivity on quantitative sensory testing had more disability and higher Quell use, but sensitivity did not predict pain outcomes.
Subjects in the experimental group used their device 381 ± 353 hours during the study.
The study was a three-month single site, controlled, randomized clinical trial. A total of 68 adult patients with a primary complaint of chronic low back pain were enrolled and randomized with equal probability to treatment with the Quell device or "treatment-as usual." Study subjects averaged 46.2 ± 2.7 years of age. All subjects used a smartphone app developed by the Pain Management Center that helps patients document and manage their pain. Outcome measures included the Brief Pain Inventory, the Pain Catastrophizing Scale, the Pain Disability Index and the Hospital Anxiety and Depression Scale. All subjects were given Quantitative Sensory Testing at baseline.
According to the Centers for Disease Control and Prevention (CDC), low back pain is the second most common cause of disability in US adults. The incidence of low back pain is as high as 12 percent of the general population at any given point in time, and nearly 25 percent of US adults report having had it at some point over any one-month period. The condition has a significant economic impact, with total costs estimated to be up to $200B annually. For those with chronic low back pain (low back pain persisting for three or more months), there are few accepted treatments that do not involve prescription medication, manipulation, invasive procedures, or surgery.
"Chronic low back pain is a major health problem and represents a natural application for Quell," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "The preliminary results from this study led by Dr. Robert Jamison are encouraging and we look forward to formal publication of the study findings."
Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress
Globe Newswire FOLLOW
May 03, 2018 11:00am Comments
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), today reported that preliminary results from a study of Quell® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12, 2018.
The study was conducted by Dr. Robert Jamison and his colleagues at the Brigham and Women's Hospital Pain Management Center in Boston, MA. The poster presentation is titled "Efficacy of high-frequency transcutaneous electrical nerve stimulation for chronic low back pain: does hypersensitivity matter?" and includes the following key findings:
Subjects in the experimental (Quell) group demonstrated reduced pain intensity compared to control subjects.
Subjects in the experimental group exhibited reduced pain interference with function and pain catastrophizing compared to the control group.
Subjects in the experimental group with greater sensitivity on quantitative sensory testing had more disability and higher Quell use, but sensitivity did not predict pain outcomes.
Subjects in the experimental group used their device 381 ± 353 hours during the study.
The study was a three-month single site, controlled, randomized clinical trial. A total of 68 adult patients with a primary complaint of chronic low back pain were enrolled and randomized with equal probability to treatment with the Quell device or "treatment-as usual." Study subjects averaged 46.2 ± 2.7 years of age. All subjects used a smartphone app developed by the Pain Management Center that helps patients document and manage their pain. Outcome measures included the Brief Pain Inventory, the Pain Catastrophizing Scale, the Pain Disability Index and the Hospital Anxiety and Depression Scale. All subjects were given Quantitative Sensory Testing at baseline.
According to the Centers for Disease Control and Prevention (CDC), low back pain is the second most common cause of disability in US adults. The incidence of low back pain is as high as 12 percent of the general population at any given point in time, and nearly 25 percent of US adults report having had it at some point over any one-month period. The condition has a significant economic impact, with total costs estimated to be up to $200B annually. For those with chronic low back pain (low back pain persisting for three or more months), there are few accepted treatments that do not involve prescription medication, manipulation, invasive procedures, or surgery.
"Chronic low back pain is a major health problem and represents a natural application for Quell," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "The preliminary results from this study led by Dr. Robert Jamison are encouraging and we look forward to formal publication of the study findings."
AKAO. This guy bought more. https://ih.advfn.com/p.php?pid=nmona&article=77291150&symbol=AKAO
CATB up AH on news
WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA, April 21-27.
The poster is titled: "Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy", which can be viewed here: Pilot Study of Sleep/Wake Classification by Leg-Worn Actigraphy.
Should be getting a press release on CYCC and ARQL any minute from the AACR conference.
Three form 4 buys. https://ih.advfn.com/p.php?pid=nmona&article=77176815&symbol=NURO
EYES. ANNUAL MEETING OF THE STOCKHOLDERS
May 16, 2018
OPK. Does this CEO buy stock every day or so? https://ih.advfn.com/p.php?pid=nmona&article=77172125&symbol=OPK
Does this CEO buy stock every day or so? https://ih.advfn.com/p.php?pid=nmona&article=77172125&symbol=OPK